Quarterly report pursuant to Section 13 or 15(d)

Note 3 - License Supplier Agreement (Details Textual)

v3.24.2.u1
Note 3 - License Supplier Agreement (Details Textual) - USD ($)
$ / shares in Units, $ in Thousands
 1 Months Ended 4 Months Ended 6 Months Ended
Sep. 26, 2023
Apr. 27, 2023
Mar. 30, 2023
Feb. 28, 2023
Oct. 29, 2018
Dec. 31, 2019
Jun. 17, 2015
Jun. 30, 2023
Contractual Obligation Development Expense           $ 81,500    
Contractual Obligation, Commercial Expense           $ 151,000    
Stock Issued During Period, Value, License Expense               $ 1,230
AnnJi [Member]                
License Agreement, Purchase Consideration       $ 3,000        
Payments to Acquire License   $ 2,000            
Acquired License Payable Within 180 Days       1,000        
Maximum Reimbursement Amount In Connection With Product Clinical Trial       10,800        
Maximum Reimbursement Amount In Connection With Certain Development Milestones       14,500        
Maximum Reimbursement Amount In Connection With Certain Drug Development Milestone       27,500        
Maximum Reimbursement Amount Upon Achievement of Sales Milestone       165,000        
Stock Issued During Period, Shares, License Expense (in shares)     11,089          
Stock Issued During Period, Value, License Expense     $ 900          
Stock Issuable During Period, Shares, Upon Enrollment of Patient (in shares) 3,688              
Stock Issuable During Period, Value, Upon Enrollment of Patient $ 300              
AnnJi [Member] | Minimum [Member]                
Sales Milestone Required for Maximum Reimbursement       75,000        
Annual Sale Threshold for Royalty Payment       50,000        
AnnJi [Member] | Maximum [Member]                
Sales Milestone Required for Maximum Reimbursement       750,000        
Annual Sale Threshold for Royalty Payment       $ 300,000        
Revogenex License [Member]                
Contractual Obligation, Maximum Future Payments             $ 3,000  
Baergic Licenses [Member] | CCHMC [Member]                
Percentage of Equity Fee           5.00%    
Polpharma [Member]                
Payments to Acquire in Process Research and Development         $ 2,000      
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Upfront Payment [Member]                
Payments to Acquire in Process Research and Development             2,000  
Percentage of Equity Fee           20.00%    
Fortress Biotech Inc [Member] | Iv Tramadol [Member] | Additional Payment [Member]                
Payments to Acquire in Process Research and Development           $ 1,000 $ 1,000  
Baergic Licenses [Member] | Upfront Payment [Member] | CCHMC [Member]                
Payments to Acquire in Process Research and Development           200    
Baergic Licenses [Member] | Upfront Payment [Member] | AZERBAIJAN                
Payments to Acquire in Process Research and Development           $ 3,000    
AnnJi [Member]                
Right to Sell Common Stock, Price Per Share (in dollars per share) $ 2.1